Specialty Pharma Canyon Takes Leech-Inspired Anticoagulant Approved In 2003 To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Iprivask, "the first direct thrombin inhibitor approved in the U.S.," was found superior to both heparin and Lovenox but fell through the cracks during pharma M&A activity, Canyon exec says.
You may also be interested in...
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use
Chronic use application may help ease FDA's reluctance to make available a much anticipated and broadly applicable anticoagulant for the acute application in the original NDA.
Will Latest Dabigatran Data Finally Topple Warfarin?
NEW ORLEANS - Boehringer Ingelheim's dabigatran etexilate had comparable efficacy and significantly lower or comparable bleeding rates to warfarin in patients with acute venous thromboembolism, according to data from the RE-COVER trial reported Dec. 6 at the American Society of Hematology meeting in New Orleans
Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin
The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use